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The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights
the need for intensifying research efforts devoted to developing new agents for preventing
or retarding the disease process. During the last few years, targeting the endogenous
cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer.
The endocannabinoid system is composed by a number of cannabinoid receptors,
including the well-characterized CB1 and CB2 receptors, with their endogenous ligands
and the enzymes related to the synthesis and degradation of these endocannabinoid
compounds. Several ﬁndings indicate that the activation of both CB1 and CB2 receptors
by natural or synthetic agonists, at non-psychoactive doses, have beneﬁcial effects in
Alzheimer experimental models by reducing the harmful β-amyloid peptide action and tau
phosphorylation, aswell as by promoting the brain’s intrinsic repair mechanisms. Moreover,
endocannabinoid signaling has been demonstrated to modulate numerous concomitant
pathological processes, including neuroinﬂammation, excitotoxicity, mitochondrial dysfunc-
tion, and oxidative stress. The present paper summarizes the main experimental studies
demonstrating the polyvalent properties of cannabinoid compounds for the treatment of
AD, which together encourage progress toward a clinical trial.
Keywords: cannabinoids, Alzheimer, CB1 receptor, CB2 receptor, β-amyloid, tau, oxidative stress, neuro-
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INTRODUCTION
Alzheimer is an age-dependent neurodegenerative process dis-
tinct from normal aging and characterized morphologically by
the presence of senile plaques, mainly composed of different
species of ﬁbrillar β-amyloid (Aβ) produced by the cleavage
of the Aβ precursor protein (APP) due to β- and γ-secretases,
and by the presence of neuroﬁbrillary tangles, mostly composed
of various isoforms of hyper-phosphorylated and nitrated tau
protein (Duyckaerts and Dickson, 2011; Ferrer, 2012). One ten-
dency of opinion proposes that Aβ triggers plaque formation, tau
hyper-phosphorylation, and disease progression (Hardy, 2009).
This may happens in a percentage of familial Alzheimer’s dis-
ease (AD) cases linked to mutations in genes encoding APP,
and presenilin 1 and presenilin 2 which are enzymes involved
in the cleavage of APP, or in Down syndrome (Bertram and
Tanzi, 2011). However, tau hyper-phosphorylation precedes Aβ
deposition in many cerebral regions in sporadic cases of AD
(Braak and Braak, 1999).
Recent studies have shown that Aβ acts as a seed of newAβ pro-
duction and deposition under appropriate conditions (Frost and
Diamond, 2010) and that abnormal tau promotes the production
and deposition of hyper-phosphorylated tau under determinate
experimental conditions (Clavaguera et al., 2009). Therefore, Aβ
and hyper-phosphorylated tau promote the progression of the
pathological process in an exponential way once these abnormal
proteins are accumulated in the brain (Goedert et al., 2010; Ferrer,
2012).
In addition to these pathological hallmarks, multiple alter-
ations converge in the pathogenesis of AD, including genetic
and environmental factors. Vascular factors and concomitant
pathologies worsen disease symptoms (Kovacs et al., 2008). Mito-
chondrial functional defects, increased production of reactive
oxygen and nitrogen species (ROS and RNS), and damage to
enzymes involved in energy metabolism are causative of nerve
cell exhaustion (Pamplona et al., 2005; Ferrer, 2009; Sultana and
Butterﬁeld, 2010).
Altered lipid composition of membranes particularly lipid rafts
(Martín et al., 2010), inﬂammatory responses (Akiyama et al.,
2000), and altered production of trophic factors, neurotransmitter
and neuromodulators, together with impaired function of degra-
dation pathways such as those related to cytoplasmic proteolysis,
autophagy, and ubiquitin–proteasome system play crucial roles as
well (Keller et al., 2000; Ferrer, 2012; Selkoe, 2012).
Neuroﬁbrillary tangles ﬁrst appear in middle age in selected
nuclei of the brain stem, later in the entorhinal cortex, and
then extend to other parts of the brain (Braak and Braak,
1999; Simic et al., 2009). Senile plaques appear ﬁrst in the
orbitofrontal and temporal cortex and then extend to the
whole cortex, diencephalic nuclei, and eventually to the cere-
bellum at terminal stages (Braak and Braak, 1999). Synaptic
loss, reduced dendritic arbors, progressive isolation of remain-
ing neurons and nerve cell loss occurs with disease progression,
and affects multiple brain regions not only the cerebral cor-
tex but also the amygdala, nuclei of the forebrain including
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Meynert nucleus, striatum, thalamus, and selected nuclei of
the brain stem thus involving multiple neurotransmitter systems
(Duyckaerts and Dickson, 2011).
Importantly, the progression from early stages of the neu-
rodegenerative process to symptomatic stages may take decades,
whereas once the cognitive impairment and dementia appear the
disease progression is much more rapid. Therefore, Alzheimer is a
relatively well-tolerated degenerative process during a long period
of time, but it may have devastating effects once thresholds are
crossed (Ferrer, 2012). These facts highlight the need to search
for treatments that act on selective targets during the silent period
of the disease, aimed at curbing or retarding disease progression
toward dementia (Ferrer, 2012; Selkoe, 2012).
During the last few years, targeting the endogenous cannabi-
noid system (ECS) has emerged as a potential therapeutic
approach to treat Alzheimer in such ﬁrst stages. Endocannabi-
noid signaling has been demonstrated to modulate the main
pathological processes occurring during the silent period of the
neurodegenerative process, including protein misfolding, neu-
roinﬂammation, excitotoxicity, mitochondrial dysfunction, and
oxidative stress. The present paper summarizes the experimental
studies demonstrating themulti-facetedproperties of cannabinoid
compounds for the treatment of AD.
THE ENDOGENOUS CANNABINOID SYSTEM
The last two decades of research have brought a tremendous
improvement in knowledge of the endocannabinoid system com-
ponents and functions under physiological and pathological
conditions. This neuromodulatory system consists of cannabinoid
receptors, endogenous ligands, and several enzymes responsible
for their synthesis and degradation (Piomelli, 2003). To date, two
subtypes of cannabinoid Gi/o-coupled receptors, CB1 and CB2,
have been fully characterized and cloned. However, cannabinoid
compounds may also bind to other receptors, such as GPR55, per-
oxisome proliferator-activated receptors PPARα and PPARγ, and
transient receptor potential vannilloid-1 (TRPV1) channels (Mac-
carrone et al., 2010; Pertwee et al., 2010). CB1 receptors are the
most abundant G protein-coupled receptors in the central neural
system, expressed in both neurons and glial cells, where they regu-
late important brain functions including cognition and memory,
emotion,motor control, feeding, and pain perception (Wilson and
Nicoll, 2002; Howlett, 2005). CB1 receptors are mostly located at
the terminals of neurons of the central and peripheral nervous
system where they act as modulators of excitatory and inhibitory
neurotransmission. Moreover, CB1 receptors are also found in
peripheral tissues, playing an important role in energy balance
and metabolism (Silvestri and Di Marzo, 2013). CB2 receptors are
localized in cells of the immune system and modulate the immune
cell migration and the release of cytokines; within the nervous
system CB2 receptors are mainly located in microglia (Cabral and
Grifﬁn-Thomas, 2009). Relatively low CB2 receptor expression
has also recently been identiﬁed in some neurons (Van Sickle et al.,
2005; Brusco et al., 2008; Onaivi et al., 2008). Further evidence
of CB2 receptor expression in neurons comes from the observa-
tion that axonal damage in one cerebellar hemisphere induced
the expression of CB2 receptors in contralateral precerebellar neu-
rons; CB2 receptor agonist facilitated neuronal survival, whereas
the selective PI3K inhibitor blocked CB2R effects on axotomized
neurons (Viscomi et al., 2009). Most of the knowledge acquired
about cannabinoid receptor pharmacology was made possible
by the study of the mechanisms of action of numerous natural,
but also synthetic, cannabinoid compounds. Among the natural
cannabinoids, the most well-known are 9-tetrahydrocannabinol
(9-THC), the main psychoactive compound of the Cannabis
sativa plant, and cannabidiol (CBD), which is devoid of any psy-
choactivity, both differing in cannabinoid receptor afﬁnity and
activity (Pertwee, 2008).
The characterization of CB1 and CB2 receptors permitted
the discovered of endocannabinoids or cannabinoids produced
and released by nerve cells. Endocannabinoids are lipid com-
pounds of the eicosanoid family derived from the degradation
of membrane phospholipids (Piomelli, 2003). The most repre-
sentative are arachidonoylethanolamine (AEA), also named anan-
damide, and 2-arachidonoylglycerol (2-AG), although several oth-
ers have also been identiﬁed, such as 2-arachidonylglyceryl ether
(2-AGE), virodhamine, and N-arachidonyldopamine (Piomelli,
2003). Endocannabinoids act as neurotransmitters since they are
synthesized and released by neurons, are able to bind and acti-
vate membrane receptors, and are inactivated by reuptake and
enzymatic degradation within the cell. However, endocannabi-
noids have two fundamental characteristics that differentiate them
from other neurotransmitters: they act as retrograde messen-
gers and they do not accumulate in the interior of synaptic
vesicles (Wilson and Nicoll, 2002). For several years, endo-
cannabinoid compounds have been supposed to be exclusively
synthesized on demand to act on cells located near their site
of synthesis, and then to be rapidly inactivated by the action
of speciﬁc degradation enzymes. However, recent studies have
shown intracellular stores of anandamide in places other than
synaptic vesicles as in adiposomes where it is sequestered and
concentrated to higher levels than in the extracellular space
(Hillard and Jarrahian, 2000; Maccarrone et al., 2010). More-
over, an active intracellular binding of anandamide to TRPV1
and PPARs suggest an additional role of anandamide as a sec-
ond messenger in intracellular signaling (Maccarrone et al., 2010).
This new scenario contemplates the possibility that anandamide
may act as an autocrine/paracrine ligand of CB receptors but
also as an intracellular ligand to TRPV1 and PPARs; more-
over, the presence of extracellular anandamide transporters would
point anandamide as an endocrine messenger (Maccarrone et al.,
2010).
Interestingly, neuronal damage can increase the production
of endocannabinoids, which may provide a defense mechanism
against toxicity (Stella et al., 1997; Marsicano et al., 2003). In
the case of AEA, the synthesis is performed from the phos-
phatidylethanolamine existing in the cell membrane by the
successive action of 2 enzymes, the N-acetyltransferase and phos-
pholipase D (PLD). AEA action is determined by two processes
that limit their availability, (i) transport from the synaptic cleft
into the cell by passive diffusion or by a selective transporter,
and (ii) the hydrolysis caused by two enzyme systems, mainly
the fatty acid amide hydrolase (FAAH) but also monoacylglycerol
lipase (MAGL; Di Marzo et al., 1994). 2-AG is the most abun-
dant endogenous cannabinoid in the brain and its concentration
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is about 200 times that of AEA (Stella et al., 1997). The forma-
tion of 2-AG is mediated by phospholipase C and diacylglycerol
lipase (DAGL), and also produced on demand. In contrast to AEA,
MAGL seems to bemore involved in 2-AGdegradation than FAAH
(Dinh et al., 2002).
Interest in the role that ECS may play in neurodegenerative
processes is based on ﬁndings revealing that the augmentation
of cannabinoid tone contributes to brain homeostasis and neu-
ron survival, suggesting that may offer protection against the
deleterious consequences of pathogenic molecules.
THE ENDOGENOUS CANNABINOID SYSTEM IN AD BRAINS
The analysis of human post-mortem samples revealed some alter-
ations in ECS composition and signaling in AD brains, although
the bestowal of such modiﬁcations in the pathophysiology of the
disease remains to be elucidated. The modiﬁcations described
for CB1 receptors in AD are ambiguous. Whereas some authors
have reported a signiﬁcant reduction in the CB1 levels in cor-
tical areas and in neurons distant from senile plaques (Ramírez
et al., 2005; Solas et al., 2013), others have described no changes
in the expression, distribution, or availability of CB1 recep-
tors in cortex and hippocampus in AD (Benito et al., 2003; Lee
et al., 2010; Mulder et al., 2011; Ahmad et al., 2013) or have
failed to dissociate CB1 receptor expression changes from normal
aging (Westlake et al., 1994). No correlation between CB1 lev-
els and any AD molecular marker or cognitive status has been
found (Solas et al., 2013). In contrast, there is no controversy
regarding the signiﬁcant increase of CB2 levels in AD brains,
mainly corresponding to receptors expressed on microglia sur-
rounding senile plaques (Ramírez et al., 2005; Solas et al., 2013).
Interestingly, expression levels of CB2 receptors correlates with
Aβ42 levels and plaque deposition, although not with cogni-
tive status (Solas et al., 2013), suggesting that such pathogenic
events induce CB2 receptor expression. Additionally, both CB1
and CB2 cannabinoid receptors in the AD brain are nitro-
sylated, and this could contribute to the impaired coupling
of these receptors to downstream effector signaling molecules
(Ramírez et al., 2005).
A few studies addressed other components of ECS in AD
human samples. The ﬁrst study analyzing endocannabinoid levels
reported no differences between AD patients and healthy con-
trols in the plasmatic concentrations of AEA and 2-AG (Koppel
et al., 2009). However, a recent lipidomic study in post-mortem
brain samples revealed lower AEA levels in midfrontal and tempo-
ral cortices in AD compared to control subjects, which inversely
correlated with the neurotoxic brain Aβ42 peptide levels and
cognitive deﬁciencies recorded in these patients, suggesting a
contribution for Aβ42-dependent AEA impairment to cognitive
dysfunction (Jung et al., 2012). Moreover, some alterations have
been found in the contents and/or activity of the enzymes related
to endocannabinoid synthesis and degradation in AD brains.
Thus, the endocannabinoid metabolizing enzyme FAAH is up-
regulated in AD both neuritic plaque-associated glia (Benito et al.,
2003) and in peripheral blood mononuclear cells (D’Addario
et al., 2012), and this could participate in the increase of AEA
degradation in the vicinity of the senile plaque. Such FAAH
overexpression may have at least two harmful consequences in
disease progression, (i) neuronal AEA availability limitation and
(ii) increase of pro-inﬂammatory molecules induced by AEA
metabolites such as arachidonic acid (Calder, 2005). An elegant
study revealed altered 2-AG signaling during late stages of AD
due to the combination of impaired MAGL recruitment and
increased DAGL levels, which subsidize synapse silencing in AD
(Mulder et al., 2011). The same study failed to detect changes
in PLD, FAAH, or TRPV1 protein levels in total hippocampal
homogenates.
CLINICAL AND PRECLINICAL EVIDENCE OF THERAPEUTIC
PROPERTIES OF CANNABINOIDS IN AD
Most of the evidence accumulated sustaining the potential thera-
peutic utility of cannabinoids in AD has been obtained by using
cellular and animal models that mimic a variety of AD-related
changes, and they will be discussed later on in this review. How-
ever, it is of note that the scarce clinical data available also support
the beneﬁcial effects of cannabinoid compounds for treating some
behavioral symptoms related to AD. Only a few clinical trials
and one case report are available on the topic so far. In all the
cases an analog of 9-THC (nabilone or dronabinol) was tested.
Interestingly, one clinical trial including 15 AD patients resulted
in a decreased severity of altered behavior and an increase in
the body weight in AD patients, who were previously refusing
food, after 6 weeks of dronabinol treatment. Side effects associ-
ated with cannabinoid administration were limited to euphoria,
somnolence, and tiredness, but these did not warrant discontinu-
ation of therapy (Volicer et al., 1997). Similarly, two pilot studies
including eight patients with dementia concluded with a reduc-
tion in night-time agitation and behavioral disturbances, without
adverse effects during the trial period with dronabinol (Walther
et al., 2006, 2011). In line with these observations, the use of the
cannabinoid receptor agonist nabilone correlatedwithprompt and
dramatic improvements in the severe agitation and aggressiveness
exhibited by an advanced AD patient who was refractory to anti-
psychotic and anxiolytic medications (Passmore, 2008). In spite of
the low number of patients included in these trials and the fact that
none of them evaluated cognitive or neurodegenerative markers,
the positive behavioral results are promising and represent valu-
able, albeit limited, information, considering that no remarkable
side effects were reported. However, the revision in 2009 of the
Cochrane Dementia and Cognitive Improvement Group Special-
ized Register found no evidences of cannabinoid effectiveness in
the improvement of behavior and other parameters of demen-
tia, and suggested that more controlled trials are needed to assess
the effectiveness of cannabinoids in the treatment of dementia
(Krishnan et al., 2009).
EFFECT OF CANNABINOIDS ON Aβ
Several in vitro and in vivo studies demonstrate that certain
cannabinoid compounds confer neuroprotection against Aβ, as
previously reported elsewhere (Ruiz-Valdepeñas et al., 2010).
Some endocannabinoids such as AEA, 2-AG, and noladin ether,
directly supplied to the cell culture or augmenting their availability
through administration of endocannabinoid reuptake inhibitors,
increased the viability of neurons after exposure to different
toxic Aβ species (Milton, 2002; Chen et al., 2011; Harvey et al.,
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2012; Janefjord et al., 2013), and reduced Aβ-induced memory
impairment in rats (van der Stelt et al., 2006). Similar posi-
tive results in the survival of neuronal cultures exposed to Aβ
peptide were obtained with exogenous cannabinoids such as
CBD (Iuvone et al., 2004; Janefjord et al., 2013), the selective
CB1 receptor agonist arachidonyl-2-chloroethylamide (ACEA;Aso
et al., 2012), the CB2 selective agonists JWH-015 and JWH-133,
and the mixed CB1/CB2 receptor agonists 9-THC, HU-210,
and WIN55,212-2 (Ramírez et al., 2005; Janefjord et al., 2013).
The neuroprotective properties of exogenous cannabinoids have
consistently been demonstrated to prevent memory deﬁcits in
Aβ-injected rats and mice for both synthetic CB1 (Haghani et al.,
2012) and CB2 selective agonists (Wu et al., 2013), as well as mixed
CB1/CB2 receptor agonists (Ramírez et al., 2005; Martín-Moreno
et al., 2011; Fakhfouri et al., 2012) and natural CBD (Martín-
Moreno et al., 2011). Moreover, chronic treatment with ACEA
(Aso et al., 2012), JWH-133 (Martín-Moreno et al., 2012; Aso et al.,
2013), or WIN55,212-2 (Martín-Moreno et al., 2012) resulted
in cognitive improvement in two different transgenic mouse
models of brain amyloidosis. The efﬁcacy of the cannabinoid
compounds in curbing the cognitive impairment was inversely
proportional to the disease progression stage at the beginning
of the treatment in the transgenic animals (Aso et al., 2012,
2013).
The mechanisms of action that underlie the cannabinoid neu-
roprotection against Aβ, which ultimatelymay lead to thememory
improvement, are multiple and are assumed to act in parallel or
interacting within them. Although most of these proposed pro-
tective mechanisms are related to the capacity of cannabinoids to
indirectly mitigate the harmful effects of Aβ, as we will discuss in
later sections of this review (i.e., inﬂammation, oxidative stress,
excitotoxicity, aberrant cellular signaling), some authors also
described direct effects of cannabinoids on Aβ processing. Thus,
stimulation of CB2 receptors produced Aβ removal by human
macrophages (Tolón et al., 2009; Wu et al., 2013) and favored
Aβ transport through the choroid plexus (Martín-Moreno et al.,
2012). This facilitation of Aβ clearance across the blood–brain
barrier (BBB) was also demonstrated for the endocannabinoid 2-
AG, a synthetic CB1/CB2 receptor agonist and MAGL inhibitors,
but no FAAH, in in vitro an in vivo BBB models (Bachmeier et al.,
2013). These ﬁndings could explain the reduction in Aβ levels and
plaque burden observed in AD mouse models chronically treated
with CB2 or CB1/CB2 receptor agonists (Martín-Moreno et al.,
2012) and MAGL inhibitors (Chen et al., 2012; Piro et al., 2012).
In contrast, no signiﬁcant contribution of CB1 receptors in Aβ
production, aggregation or clearance was reported after chronic
treatment with ACEA (Aso et al., 2012) or HU-210 (Chen et al.,
2010) in two different transgenic AD models. However, there is
a study reporting a regulatory inﬂuence of CB1 receptor on APP
processing since APP23 transgenic mice deﬁcient for CB1 receptor
exhibited reduced APP protein levels and Aβ plaque deposition,
likely due to changes in intracellular APP transport, although
the animals presented enhanced cognitive deﬁcits (Stumm et al.,
2013). Moreover, a recent publication revealed that 9-THC sig-
niﬁcantly increased the expression of neprilysin, an important
endopeptidase for Aβ degradation, but not β-site APP cleaving
enzyme 1 (BACE1), leading to a remarkable reduction of Aβ
plaques in 5xFAD APP transgenic mice (Chen et al., 2013). This
study failed, however, to clarify the speciﬁc role of CB1 or CB2
receptors in such 9-THC effect on Aβ clearance.
CANNABINOIDS ON TAU HYPER-PHOSPHORYLATION
A role for cannabinoids in another AD pathological hallmark,
tau hyper-phosphorylation, has also been described. First stud-
ies performed in cell cultures demonstrated that CBD, ACEA,
and WIN55,212-2 inhibited tau protein hyper-phosphorylation
in Aβ-stimulated PC12 neuronal cells (Esposito et al., 2006a,b).
In the case of CBD, the effect was mediated through the reduc-
tion of the phosphorylated active form of glycogen synthase
kinase 3β (GSK-3β), one of the known tau kinases (Ferrer et al.,
2005), which in turn resulted in Wnt/β-catenin pathway rescue
and consequent reduction of neuronal apoptosis (Esposito et al.,
2006a). In contrast, the ACEA and WIN55,212-2 effect on tau
hyper-phosphorylation was selectively mediated by CB1 receptor
through the down-regulation of inducible nitric oxide synthase
(iNOS) protein expression and nitric oxide (NO) production in
Aβ-stimulated astroglioma cells co-cultured with the PC12 neu-
ronal cells (Esposito et al., 2006b). In line with the described role
for CB1 receptor on tau hyper-phosphorylation, chronic treat-
ment with the CB1 selective agonist ACEA reduced the levels of
tau phosphorylated at Thr181 site in the area surrounding Aβ
plaques in treated APP/PS1 mice, probably through the ACEA-
induced reduction in GSK-3β harmful activity (Aso et al., 2012).
Moreover, a speciﬁc role for CB2 receptor in the modulation of tau
phosphorylation was also suggested. Chronic JWH-133 adminis-
tration reduced tau hyper-phosphorylation in the vicinity of Aβ
plaques in APP/PS1 mice, which may be explained by decreased
activity of GSK-3β, p38, and stress-activated protein kinase/c-Jun
NH(2)-terminal kinase (SAPK/JNK) kinases in the treated animals
(Aso et al., 2013).
Conﬁrming these observations, a recent study reported a
marked reduction in neuroﬁbrillary tangles in parkin-null, human
tau overexpressing (PK−/−/TauVLW) mice, a model of complex
frontotemporal dementia, parkinsonism, and lowermotor neuron
disease, after prolonged exposure to Sativex®, an already approved
medicine based on mixed 9-THC and CBD natural extracts
(Casarejos et al., 2013). The authors suggested the cannabinoid
potentiation of autophagy or improvement of redox state as likely
mechanisms accounting for the reduction in tau deposition.
ANTI-INFLAMMATORY PROPERTIES OF CANNABINOIDS
Neuroinﬂammation, initially manifested as microglial activation,
is a prominent feature in AD which contributes to progressive
cell damage and neuron loss (Akiyama et al., 2000; Hensley, 2010;
Sardi et al., 2011). As CB2 receptors are essentially expressed in
the immune system including microglial cells, where they are
known to inhibit microglia-mediated neurotoxicity, the main
interest in the role of cannabinoids as anti-inﬂammatory agents
in several diseases concurring with inﬂammation has focused
on compounds acting on CB2 receptors (Cabral and Grifﬁn-
Thomas, 2009). In the case of AD, several studies reported
that activation of CB2 receptors reduced the neuroinﬂammatory
response to Aβ insults in different models of the disease. After
the inoculation of Aβ into the rat or mouse brain, selective or
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mixed CB2 receptor agonists reduced microglial response and
pro-inﬂammatory molecule production in a plethora of stud-
ies (Ramírez et al., 2005; van der Stelt et al., 2006; Esposito
et al., 2007; Fakhfouri et al., 2012; Wu et al., 2013). Similarly,
selective CB2 receptor agonists decreased the number of acti-
vated microglial cells surrounding Aβ deposition and the levels
of pro-inﬂammatory cytokines in at least two APP transgenic
models (Martín-Moreno et al., 2012; Aso et al., 2013). Moreover,
the 9-THC and CBD natural mixture present in Sativex® also
blunted the microglial reactivity in a genetic tauopathy model
(Casarejos et al., 2013), although no evidence of direct impli-
cation of CB2 receptors or other receptors in such effects was
provided. In fact, other mechanisms related to ECS components
distinct from CB2 receptors could explain the anti-inﬂammatory
effects of the Sativex® preparation. As noted above, 9-THC
is a partial agonist of CB1 receptors, which could also play a
role in the AD inﬂammatory process according to a recent study
demonstrating that chronic treatment with the selective agonist
ACEA reduced the astrocytic expression of the pro-inﬂammatory
cytokine interferon-γ in APP/PS1 transgenic mice (Aso et al.,
2012). Additionally, CBD, which has no afﬁnity for CB1 or
CB2 receptors, also presents anti-inﬂammatory properties in AD
models (Esposito et al., 2006a; Martín-Moreno et al., 2011). The
precise site at which CBD could exert its neuroinﬂammatory and
neuroprotective effects is still not fully elucidated, but some ﬁnd-
ings point to the selective involvement of PPARγ in such CBD
properties (Esposito et al., 2011).
The enzymes related to AEA and 2-AG degradation also con-
tribute to modulating the inﬂammatory process in AD models.
FAAH is expressed in both neurons and astrocytes, where it may
play a role in the response to inﬂammation. In fact, an astrocyte-
speciﬁc increase in FAAH expression is markedly maintained in
neuroinﬂammatory conditions including amyloidosis, which was
assumed to contribute to the harmful processes induced by toxic
insults because of the reduction in endocannabinoid tone (Ben-
ito et al., 2003). However, cortical mouse astrocytes genetically
modiﬁed to lack FAAH exhibited a pro-inﬂammatory phenotype
when exposed to Aβ, characterized by an increase in cytokine
concentration and cell death probably due to the modiﬁcation
of signaling cascades involved in cell survival and inﬂamma-
tion, such as extracellular signal-regulated protein kinases 1 and
2 (ERK1/2), p38 mitogen-activated protein kinase (p38MAPK),
and nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB), as well as to the increase in inﬂammatory medi-
ators such as iNOS and cyclooxygenase (COX-2; Benito et al.,
2012). The authors demonstrated that these processes involved
PPAR-α, PPAR-γ, and TRPV1, but not CB1 or CB2 receptors.
Yet, the pharmacological blockade of FAAH in cell cultures did
not lead astrocytes to a pro-inﬂammatory phenotype, indicat-
ing that the observed effects in astrocytes lacking FAAH could
be due to compensatory changes that result from the poten-
tially prolonged enhancement of N-acylethanolamines. These
data suggest that an excessively prolonged enhancement of the
endocannabinoid tone may have harmful consequences. In con-
trast, the genetic inactivation of MAGL, an enzyme known to
hydrolyze endocannabinoids and generate the primary arachi-
donic acid pool for neuroinﬂammatory prostaglandins (Nomura
et al., 2011), attenuated neuroinﬂammation and lowered Aβ levels
and plaques in APP/PS1 mice (Piro et al., 2012). These observa-
tions were conﬁrmed by the pharmacological blockade of MAGL,
which recapitulated the cytokine-lowering effects through reduced
prostaglandin production, rather than enhanced endocannabi-
noid signaling.
CANNABINOID ACTIONS ON MITOCHONDRIA ACTIVITY: OXIDATIVE
STRESS AND ENERGY METABOLISM
Mitochondria are vital cellular components essential for ATP
production and calcium homeostasis. The relevance of these
organelles in neurons is even greater than in other cell types
because neurons are highly demanding energy cells mainly depen-
dent on aerobic oxidative phosphorylation, due to their limited
capacity for glycolysis. Long axons require energy transport
over long distances, and synaptic transmission depends on cal-
cium signals. Mitochondria are abundant in presynaptic nerve
terminals where they provide energy for sustained neurotrans-
mitter release. Therefore, defects in mitochondrial activity can
have severe consequences for the cell, including energetic fail-
ure associated with decreased ATP production and apoptosis
resulting from the release of death factors and impaired calcium-
buffering capacity. Moreover, alterations in the protein complexes
of the respiratory chain located in the inner mitochondrial
membrane lead to electron transport leakage that enables the
production of ROS, which may overwhelm the capacity of the
anti-oxidant systems existing in cells to counteract free radi-
cal damage, with the subsequent oxidative damage produced to
proteins, DNA, RNA, and lipids. Numerous studies have linked
mitochondrial dysfunction to neurodegenerative diseases, includ-
ing AD (Ferrer, 2009; Ankarcrona et al., 2010; Burchell et al.,
2010). Altered mitochondrial function appears early in time
in AD, even preceding the characteristic Alzheimer pathology
in mouse models, and ultimately leads to exhausted neurons
as a result of the convergence of reduced energy production,
increased energy demand, and excessive oxidative stress (Ferrer,
2009).
The anti-oxidant properties of cannabis derivatives, notably
CBD, were demonstrated early in cell cultures exposed to toxic
glutamate levels (Hampson et al., 1998, 2000). In line with these
ﬁndings, CBD prevented ROS production and lipid peroxida-
tion in PC12 neuronal cells exposed to Aβ, as well as reduced
apoptosis from reduced caspase 3 levels, and in counteracting
the Aβ-induced increase in intracellular calcium concentration
(Iuvone et al., 2004). CBD also reduced, in similar conditions,
the levels of nitrite (NO), a potent oxidant reactive molecule, as
well as the expression of iNOS, one of the enzymes responsible
for the synthesis of NO (Esposito et al., 2006b, 2011). Moreover,
other cannabinoid compounds exhibited anti-oxidant properties
in animal models of AD. Thus, the selective CB2 receptor agonist
JWH-133 reduced hydroxynonenal adducts, derived from lipid
peroxidation, and enhanced the levels of the superoxide dismu-
tases SOD1 and SOD2 in the vicinity of plaques in APP/PS1 mice,
indicating the role of CB2 receptors in reducing oxidative stress
damage and to promote responses against such damage (Aso et al.,
2013). A reduction of free radicals and mitochondrial activity
was also suggested in a mouse model of tauopathy exposed to
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chronic treatment with the Sativex® mixture of 9-THC and CBD
(Casarejos et al., 2013).
An additional topic deserving attention is the putative role
of cannabinoid receptors in the regulation of neuronal energy
metabolism. The little information available to date supports the
direct control of CB1 over neuronal respiration and energy pro-
duction. One study, using anti-CB1 receptor antibodies, revealed
CB1 receptor protein localization in approximately 30% of neu-
ronal mitochondria, which when activated by exogenous or
endogenous cannabinoids reduces the respiratory chain complex I
activity and oxygen consumption, likely through cyclic adenosine
monophosphate (cAMP) and protein kinase A (PKA) signaling
(Bénard et al., 2012). These ﬁndings are in agreement with pre-
vious observations showing that AEA, 9-THC, and HU-210, all
of them partial CB1 agonists, signiﬁcantly decreased oxygen con-
sumption and mitochondrial membrane potential (Athanasiou
et al., 2007). However, these data must be interpreted with cau-
tion as commercial anti-CB1 receptor antibodies also recognize
themitochondrial protein stomatin-like protein 2 and that the for-
merly described effect ofWIN55,212-2 onmitochondrial complex
III is in fact not detectable in isolated mitochondrial preparations
(Morozov et al., 2013).
CANNABINOIDS MODULATE NEUROTRANSMISSION
Nowadays the approved drugs for treating AD are based on
acetylcholine esterase (AChE) inhibitors, which increase the ACh
availability partially palliating this neurotransmitter deﬁciency
in AD patients, or they are non-competitive antagonists of the
N-methyl D-aspartate (NMDA) receptor, which reduce calcium
inﬂux and limit excitotoxicity. Interestingly, certain cannabinoid
compounds act on the same targets than current medications,
resulting in similar or enhanced beneﬁcial effects. For instance,
9-THC competitively inhibits AChE, thus increasing ACh levels,
as well as preventing AChE-induced Aβ aggregation by bind-
ing in the peripheral anionic site of AChE, the critical region
involved in amyloidogenesis (Eubanks et al., 2006). The synthetic
cannabinoid HU-211 acts as a stereoselective inhibitor of NMDA
receptors, and thus protects cells from NMDA induced neu-
rotoxicity (Feigenbaum et al., 1989; Eshhar et al., 1993; Nadler
et al., 1993). In the case of HU-211, its neuroprotective activ-
ity is due to the direct binding to NMDA receptors, not to
cannabinoid receptors, but the broadly accepted cannabinoid-
mediated neuroprotection against excitotoxicity can be achieved
through a number of other different mechanisms, including inhi-
bition of presynaptic glutamate release (Marsicano et al., 2003),
blockage of voltage-dependent calcium channels (Mackie and
Hille, 1992; Twitchell et al., 1997) and inhibition of calcium
release from ryanodine sensitive stores (Zhuang et al., 2005),
which mostly imply the direct or indirect participation of CB1
receptors.
OTHER EFFECTS OF CANNABINOIDS IN AD
Several other mechanisms seem to contribute to the thera-
peutic properties of cannabinoid compounds in AD, although
they have not been fully characterized. Among them, we can
note the capacity of endocannabinoids to prevent Aβ-mediated
lysosomal destabilization in cultured neurons, reducing in this
way the apoptotic signaling, which in turn sustains cell sur-
vival (Noonan et al., 2010). Compromised neurogenesis is an
early event in AD that limits neuronal replacement once pro-
gressive neuronal loss takes place in the brain, contributing to
cognitive deterioration (Lazarov and Marr, 2010). Interestingly,
AEA and CBD have been described as promoting neurogene-
sis in response to Aβ insult (Esposito et al., 2011; Tanveer et al.,
2012), suggesting an additional beneﬁcial effect of cannabinoids
in AD.
Another aspect as yet unexplored is the interaction of cannabi-
noids with neurotrophic factors in AD. Cannabinoids are capa-
ble of increasing brain-derived neurotrophic factor (BDNF;
Khaspekov et al., 2004), a neurotrophin reduced in the AD brain
(Lee et al., 2005; Peng et al., 2009), which is known to confer
protection against excitotoxicity and to promote neurogenesis
(Scharfman et al., 2005) and neuronal plasticity; all of these pro-
cesses play a role in AD. However, there is still no evidence
about the implication that such cannabinoid-induced BDNF pro-
motion could have on the cognitive or pathological aspects of
AD. Similarly, little is known about the participation of cannabi-
noid signaling in the impaired function of degradation pathways
such as autophagy and ubiquitin–proteasome, which are known
to play a relevant role in AD progression. The impairment in
these catabolic processes results in accumulation of aggregate-
prone proteins, altered mitochondria and other cellular organelles
that might exacerbate neurodegenerative process (Nixon et al.,
2005; Harris and Rubinsztein, 2011). To date, only one study has
reported beneﬁcial effects of cannabinoid-induced autophagy in
a model of tauopathy (Casarejos et al., 2013), but this has opened
the possibility of exploring in greater detail the involvement of
ECS in promoting degradation of toxic components in neurode-
generative diseases. Finally, the effect of cannabinoids on the
regulation of cerebral blood ﬂow may contribute to their poten-
tial beneﬁts on AD. A number of studies have demonstrated that
certain cannabinoids produce vasodilatation of brain blood ves-
sels and increase cerebral blood ﬂow (Ellis et al., 1995; Wagner
et al., 2001; Pacher et al., 2005; Iring et al., 2013). Consider-
ing that cerebral blood ﬂow in AD contributes to the reduction
of oxygen and nutrients in brain (Iadecola, 2004), it can be
suggested that treatments improving cerebral perfusion such as
cannabinoids are advantageous in AD. Taken together, available
information suggest that cannabinoids may have multiple effects
on AD by acting not only as anti-oxidant and anti-inﬂammatory
agents, but also modulating a plethora of factors which con-
tribute to the pathogenesis of AD as altered Aβ metabolism,
autophagy, trophic factor deﬁciencies, and impaired blood
ﬂow.
CONCLUSIONS AND THERAPEUTIC IMPLICATIONS
Considering the numerous complex pathological mechanisms
involved in the progression of AD, treatments targeting a single
causal or modifying factor offer limited beneﬁt. Cannabinoids,
however, exhibit pleiotropic activity, targeting in parallel several
processes that play key roles in AD, including Aβ and tau aber-
rant processing, neuroinﬂammation, excitotoxicity, mitochon-
drial dysfunction, and oxidative stress. Cannabinoids improve
behavioral disturbances, as well. These effects are summarized in
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FIGURE 1 | Summary of the main findings demonstrating
beneficial effects of cannabinoid compounds in AD models.
Cannabinoids may target in parallel several processes that play key
roles in AD, including Aβ and tau aberrant processing, chronic
inﬂammatory responses, excitotoxicity, mitochondrial dysfunction, and
oxidative stress, among others. Clinical data also reveal an
improvement in behavioral in patients with AD after treatment with
cannabinoids.
Figure 1. Then, because of thesewidespreadproperties of cannabi-
noid compounds, targeting the ECS could represent a unique and
reliable opportunity to advance toward an effective therapy against
the AD. Moreover, cannabinoids might represent a safe low-cost
therapy, with their natural origin and low side effects proﬁle. From
our point of view, the success of cannabinoid-based therapy in
AD could be increased taking into account two important aspects:
(i) the use of a combination of compounds that cover the whole
spectrum of therapeutic properties described for cannabinoids,
i.e., combination of CB1 and CB2 receptors agonists plus CBD,
which presents interesting neuroprotective properties spite of its
mechanism of action remaining poorly understood, and (ii) the
early initiation of the treatment in the neurodegenerative process,
which ensures the integrity of the ECS target components and
increases the possibility of curbing the exponential degenerative
progression toward dementia.
The main concerns regarding the use of cannabis derivatives in
medicine are relatedwith thepsychoactivity of some cannabinoids,
especially9-THC,whichmaydisrupt short-termmemory,work-
ing memory, and attention skills mainly acting through CB1
receptors, as well as with the potential 9-THC dependence
occurring after long-term use. However, the therapeutic effects of
cannabinoids must be clearly dissociated from the risks of abuse
and addiction linked to the recreational use of cannabis deriva-
tives. First, the CB1 agonists with potential psychoactivity used
in experimental models to demonstrate the therapeutic properties
were administered at doses substantially lower than those produc-
ing psychoactive effects and cannabis dependence (Maldonado
et al., 2011). Second, the preferred therapeutic cannabinoid com-
bination includes CBD, which is known to mitigate the negative
consequences on cognition of 9-THC administration (Fadda
et al., 2004), and therefore insure the avoidance of such unde-
sirable effects. Finally, the brain context in healthy subjects
consuming cannabis enriched in 9-THC for recreational pur-
poses is completely different from that of AD patients subjected
to very determined combinations of cannabinoid species, in
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terms of ECS organization and neuronal signaling. In conclu-
sion, in light of the polyvalent properties for the treatment of
AD and the limited side effects exhibited by these compounds,
progress toward a clinical trial to test the capacity of cannabi-
noids to curb this neurodegenerative disease seems to be fully
justiﬁed.
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